Search clinical trials for: gastric gastroesophageal carcinoma

Total 34992 results

National University Hospital, Singapore

Not yet recruiting

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers (VALUE-CHECK)

Carcinoma, Hepatocellular | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Oesophageal Cancer | GastroEsophageal Cancer

Singapore
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M07D1+PD-1 Monoclonal Antibody and BL-M07D1+PD-1 Monoclonal Antibody+Capecitabine in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

China
The First Affiliated Hospital of Xiamen University

Recruiting

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric/Gastroesophageal Junction Adenocarcinoma

China
Fudan University

Recruiting

Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin

Gastric / Gastroesophageal Junction Adenocarcinoma

China
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage... and other conditions
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Gastroesophageal Cancer

United States, Israel, Taiwan, Korea, Republic of
Peking University
Gracell Biopharmaceuticals, Inc.

Recruiting

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
LaNova Medicines Zhejiang Co., Ltd.

Not yet recruiting

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
Zhejiang Cancer Hospital

Recruiting

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Gastric Cancer | Colorectal Cancer | Pancreatic Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma | Liver Cancer Stage IV

China
AstraZeneca

Recruiting

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer | Gastroesophageal Junction Cancer

Canada, Spain, United Kingdom, China, France, Italy, Vietnam, Germany, United States, India, Taiwan, Thailand, Hong Kong, Japan, Switzerland, Poland
Akeso

Not yet recruiting

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric and Gastroesophageal Junction Adenocarcinoma
GC Cell Corporation

Not yet recruiting

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Australia
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; Oncolys BioPharma Inc

Recruiting

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Boehringer Ingelheim

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer | Esophageal Adenocarcinoma | Metastatic Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Harbin Medical University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Fujian Medical University

Recruiting

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Overall Response Rate

China
Kyowa Kirin, Inc.

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
Gruppo Oncologico del Nord-Ovest

Not yet recruiting

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease (TRINITY)

Gastric Cancer | HER2-positive Gastric Cancer

Italy
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | GastroEsophageal Cancer

United States
Wu Jun

Not yet recruiting

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

Adenocarcinoma | Gastric Cancer | GastroEsophageal Cancer

China
ModeX Therapeutics, An OPKO Health Company

Not yet recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Cervical Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Prostate Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Colon Cancer | Thyroid Cancer | Renal Cancer | Biliary Tract Cancer | Hepatocellular Cancer | GastroEsophageal Cancer
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

China
RemeGen Co., Ltd.

Recruiting

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
AstraZeneca

Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Gastric Cancer | Pancreatic Adenocarcinoma | Gastroesophageal Junction Cancer

United States, Spain, United Kingdom, Korea, Republic of, Japan, Taiwan, Malaysia, Canada, Singapore, Moldova, Republic of, Australia, Georgia
AskGene Pharma, Inc.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
LianBio LLC

Recruiting

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
National Cancer Institute (NCI)

Recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Harbin Medical University

Not yet recruiting

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd

Recruiting

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Locally Advanced Unresectable or Metastatic Gastric Cancer | Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma (Siewert II-III)

China
RemeGen Co., Ltd.

Recruiting

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Fudan University

Recruiting

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer (Miracle-G)

Adenocarcinoma | Metastatic Cancer | Metastatic Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Oligometastatic Disease | Stomach Neoplasm | Adenocarcinoma of the Stomach | Gastroesophageal-junction Cancer | Metastatic Adenocarcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

China
University of California, Davis
National Cancer Institute (NCI)

Recruiting

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) (LIVELONG)

Oligoprogressive | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Small Bowel Cancer | Intrahepatic Cholangiocarcinoma | Gall Bladder Cancer | Extrahepatic Cholangiocarcinoma | Appendiceal Cancer | Biliary Cancer | Gastroesophageal-junction Cancer

United States
Suzhou Transcenta Therapeutics Co., Ltd.

Not yet recruiting

Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Gastric Cancer | Advanced Cancer | Gastroesophageal-junction Cancer
Xiaofeng Chen

Recruiting

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Neonc Technologies, Inc.

Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Gastroesophageal Junction... and other conditions

United States
Toray Industries, Inc

Recruiting

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Japan
Ukrainian Society of Clinical Oncology

Recruiting

Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR)

Stomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma | Advanced Gastroesophageal Junction Adenocarcinoma

Ukraine
Sun Yat-sen University

Recruiting

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

Gastric or Gastroesophageal Junction Adenocarcinoma

China
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

HER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction Adenocarcinoma

Austria, Belgium, Germany, Italy
Novartis Pharmaceuticals

Recruiting

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

Glioblastoma Multiforme | Gastroesophageal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma

Netherlands, Spain, Israel, United States, Switzerland
Akeso

Recruiting

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

China
NextPoint Therapeutics, Inc.

Recruiting

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Metastatic Malignant Neoplasm

United States
Sichuan University

Not yet recruiting

To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Gastric Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Sun Yat-sen University

Recruiting

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.

Adenocarcinoma of Stomach

China
Fog Pharmaceuticals, Inc.

Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Cancer | Gastric Cancer | Colorectal Cancer | Solid Tumor | Metastatic Cancer | Adenomatous Polyposis Coli | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Carcinoma | Locally Advanced Solid Tumor | Non-small Cell Lung Cancer Stage IIIB | Gastroesophageal-junction Cancer | Non-Small... and other conditions

United States

Search clinical trials for: gastric gastroesophageal carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations